Adventitious Agents: Issues and Considerations during Pre-Approval Reviews and Inspections

References

1. 1.↵
   GlaxoSmithKline statement on new information relating to manufacture of Rotarix (rotavirus vaccine), March 22, 2010.
2. 2.↵
   ICH Q5A (R1)—Quality of Biological Products: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin.
3. 3.↵
   Guidance for Industry: CGMP for Phase I Investigational Drugs, July 2008.
4. 4.↵
   1. Miller D. L.,
   2. Ross J.

   Vaccine INDs: review of clinical holds. Vaccine 2005, 23 (9), 1099–1101.

   OpenUrlPubMed
5. 5.
   Code of Federal Regulations (CFR) Title 21, Parts 210, 211, 312, and 600, U.S. Government Printing Office, Washington DC, 2011.
6. 6.
   Guidance for Industry: Content and Format of Chemistry, Manufacturing and Controls and Establishment Description for a Vaccine or Related Product, 1999.